Cited by 164Schizophrenia research and treatmentNeuroscience and Neuropharmacology ResearchNeurotransmitter Receptor Influence on Behavior

Behavioral and neurochemical consequences of cortical oxidative stress on parvalbumin-interneuron maturation in rodent models of schizophrenia

Open access
Powell, Susan B., Sejnowski, Terrence J., Behrens, M. Margarita·2012·Neuropharmacology

Abstract

Oxidative stress, in response to the activation of the superoxide-producing enzyme Nox2, has been implicated in the schizophrenia-like behavioral dysfunction that develops in animals that were subject to either neonatal NMDA receptor-antagonist treatment or social isolation. In both of these animal models of schizophrenia, an environmental insult occurring during the period of active maturation of the fast-spiking parvalbumin-positive (PV+) interneuronal circuit leads to a diminished expression of parvalbumin in GABA-inhibitory neurons when animals reach adulthood. The loss of PV+ interneurons in animal models had been tentatively attributed to the death of these neurons. However, present results show that for the perinatal NMDA-R antagonist model these interneurons are still alive when animals are 5-6 weeks of age even though they have lost their phenotype and no longer express parvalbumin. Alterations in parvalbumin expression and sensory-evoked gamma-oscillatory activity, regulated by PV+ interneurons, are consistently observed in schizophrenia. We propose that cortical networks consisting of faulty PV+ interneurons interacting with pyramidal neurons may be responsible for the aberrant oscillatory activity observed in schizophrenia. Thus, oxidative stress during the maturation window for PV+ interneurons by alteration of normal brain development, leads to the emergence of schizophrenia-like behavioral dysfunctions when subjects reach early adulthood.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2011.01.049

Cites

161 of 161 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Inhibition of NMDARs during early life causes a persistent decrease in the number of parvalbumin-immunoreactive cells without cell death, suggesting that disruption of NMDAR-mediated signaling impairs maturation of these cells.

    “Inhibition of NMDARs during early life causes a persistent decrease in number of parvalbumin-immunoreactive cells without cell death (Powell et al., 2012), suggesting that disruption of NMDAR-mediated signaling impairs maturation of these cells.”
  • Parvalbumin interneurons are especially vulnerable to NMDAR hypofunction during development.

    “However, PVI are especially vulnerable to NMDAR hypofunction during development (Abekawa et al., 2007; Powell et al., 2012; Wang et al., 2008; Wang et al., 2013).”
  • In NOX-2 knockout mice, parvalbumin interneurons are protected from postnatal ketamine treatment, indicating a crucial role of NOX in parvalbumin interneuron impairment following early-life NMDAR blockade.

    “In NOX-2 knockout mice, PVI are protected from a postnatal ketamine treatment, indicating a crucial role of NOX in the PVI impairment following early-life blockade of NMDAR (Powell et al., 2012).”
  • Some human and animal data suggest that PV-INs may remain present but cease to express PV, although a definitive conclusion cannot yet be drawn.

    “Some human and animal model data suggest that formerly PV-INs are still present but cease to express PV, though a definitive conclusion cannot be drawn at this point [7,[18][19][20].”

    From Parvalbumin interneuron vulnerability and brain disorders (2021) · cites this paper as [18]

  • Redox dysregulation/oxidative stress halts normal PVI maturation in the prefrontal cortex without causing their death, possibly via epigenetic mechanisms.

    “Based on the fact that a peripubertal antioxidant treatment can abolish oxidative stress and rescue PVI/PNN deficit in the NVHL rat model,41 we propose a hypothesis in which redox dysregulation/oxidative stress halts normal PVI maturation in the prefrontal cortex without causing their death,82 possibly via epigenetic mechanisms.102, 103”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Melle I Larsen TK Haahr U Friis S Johannesen JO Opjordsmoen S Rund BR Simonsen E Vaglum P McGlashan T Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis Arch Gen Psychiatry 2008 65 634 640 18519821
  2. Sircar R Rudy JW Repeated neonatal phencyclidine treatment impairs performance of a spatial task in juvenile rats Ann N Y Acad Sci 1998 844 303 309 9668687

Cited by

Sorted by citations

Authors
Powell, S. B., Sejnowski, T. J., & Behrens, M. M.
Affiliations
  • University of California San Diego (US)
  • Salk Institute for Biological Studies (US)
Corresponding author
Behrens, M. Margarita
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2012-03
Volume
62
Issue
3
Pages
1322-1331
ISSN
0028-3908 (ISSN-L)
OpenAlex
W2132951361
Cited by
164
References
161
Citations by year
2026: 5 · 2025: 5 · 2024: 6 · 2023: 4 · 2022: 6 · 2021: 8 · 2020: 12 · 2019: 9 · 2018: 8 · 2017: 12 · 2016: 15 · 2015: 19 · 2014: 20 · 2013: 15 · 2012: 16
FWCI
12.04
Type
journal article
Language
en
Open access
Locations
  • Neuropharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute of Mental Health (MH091407-01)
  • Howard Hughes Medical Institute
  • NARSAD
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
schizophrenia, oxidative stress, parvalbumin interneurons, NMDA receptor antagonists, social isolation, NOX2, superoxide, GABAergic neurons, gamma oscillations, perinatal brain development, rodent models, neurochemical changes
MeSH terms
Animals, Cerebral Cortex, Disease Models, Animal, Humans, Interneurons, Motor Activity, Parvalbumins, Rodentia, Schizophrenia, Oxidative Stress, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review